intranasal oxytocin in the treatment of schizophrenia
Phase 2
- Conditions
- schizophrenia.schizophrenia
- Registration Number
- IRCT201202251556N35
- Lead Sponsor
- Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Age between 18-50, Diagnosis of Schizophrenia based on DSM IV 3 chronic Schizophrenia( duration of the disorder>2 years), Minimum Score of 60 on Positive and Negative Scale
Exclusion Criteria
1- Substance dependence,2- IQ <70, 3-any other mental disorder on axis I, 4-Any serious medical or neurological problem ,5- receiving ECT during the last 14 days, 6- hepatic disease
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Severity of schizophrenia. Timepoint: Baseline and weeks 2-4-6-8 after beginig of treatment. Method of measurement: Positive and Negative Syndrome Scale (PANSS).
- Secondary Outcome Measures
Name Time Method